Resources
25 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 10/7/2019 (updated 3/25/2024)
An Introduction to Harm Reduction Webinar Presentation and Materials
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
Posted 9/8/2023 (updated 3/26/2024)
As suicide has become a major health concern in the United States, September 2023 is recognized as Suicide Prevention Month. The National Institute of Mental Health has put together a digital toolkit for Suicide Prevention Month to raise awareness. Resources are provided for multiple online platforms for the public to share which focus on recognizing the warning signs for suicide and how to get people the help they need.
Posted 10/10/2023 (updated 3/27/2024)
The University of Rochester, a RCORP-Rural Center of Excellence on SUD Prevention, has 988 Lifeline posters available for download on their website. The national 988 Suicide & Crisis Lifeline was launched in July 2023 and provides a way for individuals experiencing a suicidal, mental health, or substance use disorder crisis to receive urgent help 24/7. Spreading awareness of the 988 Lifeline is important as it can help residents in rural areas obtain treatment and help quickly.
Posted 8/23/2022 (updated 3/27/2024)
This observational study of 719 612 pharmacy claims data shows that OOP costs of naloxone grew substantially beginning in 2016. However, OOP costs did not increase for all patients and all brands of naloxone but primarily for uninsured patients and for the Evzio brand. The findings suggest that the OOP cost of naloxone has been an increasingly substantial barrier to naloxone access for uninsured patients, a population that constitutes nearly one-fifth of adults with opioid use disorder.
Posted 4/4/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration (FDA) announced that the makers of Narcan, an opioid overdose treatment, have the agency’s approval to make the drug widely available over the counter (OTC). Narcan is the brand name of the drug naloxone, a fast-acting overdose reversal. Until now, availability varied by state – typically restricted to licensed health care providers, approved opioid overdose programs, and first responders. This is an important consideration for rural counties given that research shows that these areas are nearly three times more likely than metropolitan counties to be a low-dispensing county for naloxone.
Posted 4/11/2023 (updated 3/27/2024)
The first phase of the campaign created by the White House Office of National Drug Control Policy (ONDCP) and Ad Council was launched to education young people on the dangers of fentanyl and the life-saving effects of Naloxone, a medicine that reverses opioid-related overdoses. This campaign expands on the Ad Council's The Real Deal on Fentanyl platform.
Posted 11/1/2022 (updated 3/27/2024)
Last year, the National Association of County and City Health Officials (NACCHO) launched a resource meant to help local health departments (LHD) prevent or mitigate potentially traumatic events, known as adverse childhood experiences (ACEs). The Suicide, Overdose, and Adverse Childhood Experiences Prevention Capacity Assessment Tool (SPACECAT) allows LHDs to make an internal assessment of their capacity to address and prevent a still-growing public health issue.
Posted 6/6/2022 (updated 3/27/2024)
Whether an opioid overdose death is unintentional or intentional (i.e., suicide), it can be difficult to disentangle. The suffering and hopelessness associated with addiction often lead to indifference to living or dying and to extreme risk taking. In this presentation, examples were described and presented from an opioid-specific suicide prevention training module that is part of the SafeSide Prevention learning program
Posted 7/21/2023 (updated 3/28/2024)
Disparities in access to naloxone exist and organizations are working to remove some of these barriers by utilizing innovative methods such as vending machines to distribute the overdose medication. This provides life-saving medication in an accessible way to everyone, although laws vary state to state on the distribution of these tools. More information on naloxone vending machines can be found in these resources by the Bureau of Justice Assistance's (BJA) Comprehensive Opioid, Stimulant, and Substance Use Program (COSSUP) and The Network for Public Health Law.